JP2011525902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525902A5 JP2011525902A5 JP2011515663A JP2011515663A JP2011525902A5 JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5 JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5
- Authority
- JP
- Japan
- Prior art keywords
- pathogen
- immune response
- subject
- composition
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13314008P | 2008-06-25 | 2008-06-25 | |
| US61/133,140 | 2008-06-25 | ||
| PCT/IB2009/006260 WO2009156852A1 (en) | 2008-06-25 | 2009-06-25 | Rapid responses to delayed booster immunisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525902A JP2011525902A (ja) | 2011-09-29 |
| JP2011525902A5 true JP2011525902A5 (https=) | 2012-08-09 |
| JP5712126B2 JP5712126B2 (ja) | 2015-05-07 |
Family
ID=41171092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515663A Expired - Fee Related JP5712126B2 (ja) | 2008-06-25 | 2009-06-25 | 遅延型追加刺激免疫処置に対する迅速な応答 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9421251B2 (https=) |
| EP (1) | EP2310045A1 (https=) |
| JP (1) | JP5712126B2 (https=) |
| CA (1) | CA2729248A1 (https=) |
| WO (1) | WO2009156852A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| CA2439111A1 (en) | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| TWI365074B (en) | 2004-10-07 | 2012-06-01 | Wyeth Corp | Multivalent avian influenza vaccines |
| WO2006050394A2 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
| PT1861120T (pt) | 2005-03-23 | 2016-08-18 | Glaxosmithkline Biologicals Sa | Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória |
| US20100158943A1 (en) * | 2005-11-04 | 2010-06-24 | Novartis Vaccines And Diagnostics Srl | Administration routes for priming/boosting with influenza vaccines |
| US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
| US20080014217A1 (en) | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
| HRP20140488T1 (hr) | 2006-07-17 | 2014-07-04 | Glaxosmithkline Biologicals S.A. | Cjepivo protiv influence |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
-
2009
- 2009-06-25 JP JP2011515663A patent/JP5712126B2/ja not_active Expired - Fee Related
- 2009-06-25 EP EP09769663A patent/EP2310045A1/en not_active Withdrawn
- 2009-06-25 WO PCT/IB2009/006260 patent/WO2009156852A1/en not_active Ceased
- 2009-06-25 US US12/999,848 patent/US9421251B2/en not_active Expired - Fee Related
- 2009-06-25 CA CA2729248A patent/CA2729248A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525902A5 (https=) | ||
| Kim et al. | Influenza vaccines: Past, present, and future | |
| JP6308500B2 (ja) | 強化された免疫賦活化剤 | |
| Jabbal-Gill | Nasal vaccine innovation | |
| Alving et al. | Adjuvants for human vaccines | |
| Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
| Levitz et al. | Beyond empiricism: informing vaccine development through innate immunity research | |
| Mori et al. | The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses | |
| Skene et al. | Saponin-adjuvanted particulate vaccines for clinical use | |
| Yusuf et al. | Current prospects and future challenges for nasal vaccine delivery | |
| Riese et al. | Intranasal formulations: promising strategy to deliver vaccines | |
| Pellegrini et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database | |
| Tetsutani et al. | Adjuvants in influenza vaccines | |
| de Haan et al. | Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration | |
| CN109364244B (zh) | 黏膜佐剂和递送系统 | |
| Dehghan et al. | Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants | |
| JP2003523310A (ja) | 新規インフルエンザウイルスワクチン組成物 | |
| TW200722101A (en) | Novel composition | |
| Cheong et al. | Epigallocatechin-3-gallate as a novel vaccine adjuvant | |
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| Chua et al. | Opinion: making inactivated and subunit-based vaccines work | |
| JP2015529677A5 (https=) | ||
| de Veer et al. | New developments in vaccine research--unveiling the secret of vaccine adjuvants | |
| Suresh et al. | Evaluation of mucosal adjuvants to chitosan-nanoparticle-based oral subunit vaccine for controlling salmonellosis in broilers | |
| RU2017140856A (ru) | Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц |